A new fixed-dose combination of subcutaneous (SC) of pertuzumab + trastuzumab demonstrated non-inferiority compared with the same regimen which was administered intravenously (IV), with comparable efficacy and safety. This new formulation offers patients with human epidermal growth factor 2 (HER2)-positive breast cancer a faster and simpler method of pertuzumab + trastuzumab administration.
Tan et al. presented the first results from the FeDeriCa study which was designed to assess the pharmacokinetics, efficacy, and safety of a novel SC fixed-dose combination of pertuzumab + trastuzumab compared with IV trastuzumab + pertuzumab in patients with HER2-positive early breast cancer in the neoadjuvant-adjuvant setting . The new SC formulation was developed using recombinant human hyaluronidase in one vial and is administered into the thigh over 5-8 minutes. Eligible patients had centrally confirmed HER2-positive invasive breast cancer (tumour >2 cm, or no...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Palbociclib not statistically superior to capecitabine in PFS Next Article
Sensory peripheral neuropathy after taxane treatment is not uncommon »